SG11202001077UA - Novel acylated insulin analogues and uses thereof - Google Patents

Novel acylated insulin analogues and uses thereof

Info

Publication number
SG11202001077UA
SG11202001077UA SG11202001077UA SG11202001077UA SG11202001077UA SG 11202001077U A SG11202001077U A SG 11202001077UA SG 11202001077U A SG11202001077U A SG 11202001077UA SG 11202001077U A SG11202001077U A SG 11202001077UA SG 11202001077U A SG11202001077U A SG 11202001077UA
Authority
SG
Singapore
Prior art keywords
insulin analogues
acylated insulin
novel acylated
novel
analogues
Prior art date
Application number
SG11202001077UA
Inventor
Grith Olsen
Bo Hansen
Lauge Schäffer (Deceased)
Ingrid Pettersson
Rita Slaaby
Jakob Brandt
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SG11202001077UA publication Critical patent/SG11202001077UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
SG11202001077UA 2017-08-17 2018-08-16 Novel acylated insulin analogues and uses thereof SG11202001077UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186612 2017-08-17
EP17204872 2017-12-01
PCT/EP2018/072191 WO2019034726A1 (en) 2017-08-17 2018-08-16 Novel acylated insulin analogues and uses thereof

Publications (1)

Publication Number Publication Date
SG11202001077UA true SG11202001077UA (en) 2020-03-30

Family

ID=63165388

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001077UA SG11202001077UA (en) 2017-08-17 2018-08-16 Novel acylated insulin analogues and uses thereof

Country Status (19)

Country Link
US (2) US10919949B2 (en)
EP (1) EP3668892A1 (en)
JP (2) JP2020531451A (en)
KR (1) KR20200038502A (en)
CN (1) CN111032685A (en)
AU (1) AU2018317810A1 (en)
BR (1) BR112020002364A2 (en)
CA (1) CA3071686A1 (en)
CL (1) CL2020000310A1 (en)
CO (1) CO2020002500A2 (en)
IL (1) IL272394A (en)
MA (1) MA49896A (en)
MX (1) MX2020001434A (en)
PE (1) PE20211264A1 (en)
PH (1) PH12020550050A1 (en)
RU (1) RU2020108281A (en)
SG (1) SG11202001077UA (en)
TW (1) TW201917134A (en)
WO (1) WO2019034726A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (en) 2005-12-28 2011-12-30 Novo Nordisk A/S COMPOSITIONS THAT INCLUDE AN INSULIN ACILADA AND ZINC AND METHOD OF PRODUCTION OF SUCH COMPOSITIONS.
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DK58285D0 (en) 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5616729A (en) 1986-07-17 1997-04-01 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
DK105489D0 (en) 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
DK155690D0 (en) 1990-06-28 1990-06-28 Novo Nordisk As NEW PEPTIDES
DK10191D0 (en) 1991-01-22 1991-01-22 Novo Nordisk As HIS UNKNOWN PEPTIDES
DK33591D0 (en) 1991-02-27 1991-02-27 Novo Nordisk As
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
JP4187796B2 (en) 1996-12-20 2008-11-26 ノボ ノルディスク アクティーゼルスカブ N-terminal extension protein expressed in yeast
DK1146896T3 (en) 1999-01-26 2002-09-02 Lilly Co Eli Formulations containing monodisperse hexameric acylated insulin analogues
AU5144400A (en) * 1999-05-19 2000-12-05 Xencor, Inc. Novel proteins with insulin-like activity useful in the treatment of diabetes
WO2001049742A1 (en) 1999-12-29 2001-07-12 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
WO2005054291A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
ES2428510T3 (en) 2005-02-02 2013-11-08 Novo Nordisk A/S Insulin derivatives
ATE482977T1 (en) * 2006-02-27 2010-10-15 Novo Nordisk As INSULIN DERIVATIVES
CN101541830A (en) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 Protease resistant insulin analogues
WO2009022013A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP2012512900A (en) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション YL insulin-like growth factor with high activity against insulin receptor
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
TW201105346A (en) 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2011159882A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Novel stabilized insulin agonists
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011163460A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
CN103119057B (en) 2010-06-24 2016-06-15 印第安纳大学研究及科技有限公司 Insulin prodrug based on amide
EP2598527A4 (en) 2010-07-28 2014-01-08 Smartcells Inc Recombinantly expressed insulin polypeptides and uses thereof
JP2013540771A (en) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス Novel N-terminally modified insulin derivative
AR087433A1 (en) 2011-08-08 2014-03-26 Merck Sharp & Dohme N-GLICOSILATED INSULIN ANALOGS
JP6392123B2 (en) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ CTP-based insulin analog for diabetes treatment
CN104364262A (en) 2011-12-21 2015-02-18 诺沃—诺迪斯克有限公司 N -terminally modified insulin derivatives
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
JP6735561B2 (en) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs
EP2931301B2 (en) 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US20160193154A1 (en) 2013-07-24 2016-07-07 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (en) * 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
JP6701208B2 (en) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Lipidated amide insulin prodrug
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
JP6484337B2 (en) 2014-11-21 2019-03-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Insulin receptor partial agonist
EP3250225A1 (en) 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
EP3268384B1 (en) 2015-03-10 2021-11-03 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
EP3280450A4 (en) 2015-04-08 2018-12-12 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
US20180244743A1 (en) * 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
TW201717998A (en) 2015-08-25 2017-06-01 諾佛 儂迪克股份有限公司 Novel insulin derivatives and the medical uses hereof
US10745457B2 (en) 2015-09-02 2020-08-18 Merck Sharp & Dohme Corp. Process for obtaining insulin with correctly formed disulfide bonds

Also Published As

Publication number Publication date
CA3071686A1 (en) 2019-02-21
BR112020002364A2 (en) 2020-09-01
TW201917134A (en) 2019-05-01
US20190194285A1 (en) 2019-06-27
JP2020531451A (en) 2020-11-05
PH12020550050A1 (en) 2020-10-19
MA49896A (en) 2020-06-24
PE20211264A1 (en) 2021-07-15
CO2020002500A2 (en) 2020-06-09
CL2020000310A1 (en) 2020-07-10
WO2019034726A1 (en) 2019-02-21
RU2020108281A (en) 2021-08-26
RU2020108281A3 (en) 2022-03-09
CN111032685A (en) 2020-04-17
US10919949B2 (en) 2021-02-16
EP3668892A1 (en) 2020-06-24
US20210094999A1 (en) 2021-04-01
AU2018317810A1 (en) 2020-03-19
IL272394A (en) 2020-03-31
JP2022105082A (en) 2022-07-12
MX2020001434A (en) 2020-03-20
KR20200038502A (en) 2020-04-13

Similar Documents

Publication Publication Date Title
HUE057965T2 (en) Novel promoter and use thereof
IL293377B1 (en) Hsd17b13 variants and uses thereof
SG11201705765VA (en) Novel promoter and uses thereof
IL256137B (en) Keratoprosthesis and uses thereof
ZA201802017B (en) Novel insulin analogs and use thereof
IL268593A (en) Polypeptide variants and uses thereof
ZA201907833B (en) Heteroarylphenylaminoquinolines and analogues
IL270813A (en) Acylated insulin compound
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
IL253600A0 (en) Insulin analogues and compositions comprising same
EP3609504A4 (en) Novel oxaborole analogs and uses thereof
GB201711749D0 (en) Cyclosporin analogues and uses thereof
HK1253725A1 (en) Novel antimicrobial peptide and use thereof
IL271073A (en) B4galt1 variants and uses thereof
IL264473A (en) Gpr156 variants and uses thereof
IL272394A (en) Novel acylated insulin analogues and uses thereof
HK1251724A1 (en) Elastic piece and terminal
EP3696163C0 (en) Novel pseudoceramide compound and use thereof
IL273671A (en) Cornulin (crnn) variants and uses thereof
IL275211A (en) Fast and partition-resilient blockchains
IL263682A (en) Lantibiotic variants and uses thereof
HK1247220A1 (en) Cyclic galanin-analogs and uses thereof
GB201714409D0 (en) Oligonucleotides and analogues thereof
HK1256605A1 (en) Benzenesulfonyl-asymmetric ureas and medical uses thereof
GB201401673D0 (en) Esculentin-2CHa peptide and analogues thereof